Selonterra, a biotech company focused on Parkinson’s research, has received a $2.5 million grant from The Michael J. Fox Foundation to support its work on Soturi, an innovative digital therapeutic solution for people with Parkinson’s disease. This groundbreaking grant marks a significant milestone in the fight against Parkinson’s disease, a progressive neurological disorder affecting millions worldwide.
Parkinson’s disease causes tremors, stiffness, and difficulty with movement and coordination, making it challenging to perform everyday tasks. Selonterra’s work on Soturi can potentially improve people’s lives with Parkinson’s disease by providing a practical, accessible, and personalized treatment option.
Parkinson’s and Selonterra
Parkinson’s disease is a progressive neurological disorder. It affects millions of people worldwide and there is currently no cure. The Michael J. Fox Foundation‘s aim is to change this through research and advocacy.
Selonterra is a biotech company developing new therapies for Parkinson’s disease using cutting-edge technologies. The company’s research focuses on developing digital therapeutics to help people with Parkinson’s disease manage their symptoms and improve their quality of life.
Selonterra’s Work on Soturi
Soturi is a mobile application designed to help people with Parkinson’s disease manage their symptoms and improve their overall health and wellbeing. The app uses a combination of personalized coaching, cognitive training, and physical exercise to help users improve their balance, coordination, and mobility.
The use of technology has become the cornerstone of modern-day therapeutics. Digital therapeutics like Soturi have the potential to significantly impact the lives of people living with Parkinson’s disease. These therapies are convenient, accessible, and tailored to each individual’s needs, making them an effective treatment option for many people.
The Potential Impact of Soturi
Selonterra’s work on Soturi can potentially improve the lives of millions of people with Parkinson’s disease. By providing a practical, accessible, and personalized treatment option, Soturi can help people manage their symptoms and improve their overall health and wellbeing.
The grant of $2.5 million from The Michael J. Fox Foundation to Selonterra is a significant milestone in the fight against Parkinson’s disease. With this funding, Selonterra can continue its essential work on Soturi and bring this innovative digital therapeutic to people with Parkinson’s disease worldwide.
The company’s work is far from over. Selonterra plans to use the funding to develop Soturi further and explore other potential treatments for Parkinson’s disease. By continuing to push the boundaries of Parkinson’s research, Selonterra can help pave the way toward a cure for this debilitating condition.
The ongoing efforts of The Michael J. Fox Foundation and other organizations dedicated to Parkinson’s research give hope to millions of people affected by this debilitating condition.